业界动态国内医卫资讯
口服IL-23拮抗剂Icotrokinra改善PsA症状
Medscape News · 2026-11-12 14:47
摘要
这项3期试验发现关节反应、身体功能和皮肤清除均有改善,16周时未出现新的安全性信号。Medscape Medical News
English
Oral IL-23 Antagonist Icotrokinra Improves PsA Symptoms
The phase 3 trial finds improvements in joint response, physical function, and skin clearance, with no new safety signals at 16 weeks. Medscape Medical News